A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

Trial Profile

A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs ACP 01 (Primary)
  • Indications Peripheral ischaemia
  • Focus Therapeutic Use
  • Sponsors Hemostemix
  • Most Recent Events

    • 01 Sep 2016 Status changed from suspended to recruiting, as per Hemostemix media release.
    • 01 Sep 2016 According to a Hemostemix media release, data collection and patient follow-up are ongoing. Company anticipate to continue with the enrollment of new patients in September without compromising patient safety or data integrity. The termination of the Criterium contract is not impacting our ability to continue with the trial. Company is enabling much faster enrollment in the future through rapid expansion of the number of trial sites.
    • 28 Jun 2016 Status changed from recruiting to suspended, as per Hemostemix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top